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Abstract: Inhaled bronchodilator medications are central to the management of COPD and are 
frequently given on a regular basis to prevent or reduce symptoms. While short-acting bron-
chodilators are a treatment option for people with relatively few COPD symptoms and at low 
risk of exacerbations, for the majority of patients with significant breathlessness at the time of 
diagnosis, long-acting bronchodilators may be required. Dual bronchodilation with a long-acting 
β
2
-agonist and long-acting muscarinic antagonist may be more effective treatment for some of 
these patients, with the aim of improving symptoms. This combination may also reduce the rate of 
exacerbations compared with a bronchodilator-inhaled corticosteroid combination in those with 
a history of exacerbations. However, there is currently a lack of guidance on clinical indicators 
suggesting which patients should step up from mono- to dual bronchodilation. In this article, 
we discuss a number of clinical indicators that could prompt a patient and physician to consider 
treatment escalation, while being mindful of the need to avoid unnecessary polypharmacy. These 
indicators include insufficient symptomatic response, a sustained increased requirement for rescue 
medication, suboptimal 24-hour symptom control, deteriorating symptoms, the occurrence of 
exacerbations, COPD-related hospitalization, and reductions in lung function. Future research 
is required to provide a better understanding of the optimal timing and benefits of treatment 
escalation and to identify the appropriate tools to inform this decision.
Keywords: COPD, dual bronchodilation, monobronchodilation, ICS, triple therapy
Introduction
Bronchodilators are a cornerstone of COPD treatment, commonly provided on a 
regular basis to reduce or prevent symptoms.1 While short-acting bronchodilators are 
an option for patients with occasional dyspnea at low risk of exacerbations, their use 
as regular treatment is not recommended.1 The majority of patients have breathless-
ness leading to exercise limitation at the time of diagnosis, and may require more 
intensive treatment than short-acting bronchodilators alone. For these patients, whether 
or not they are also at higher risk of exacerbations, long-acting bronchodilators (as 
monotherapy or in combination) are recommended as a preferred treatment choice 
in current guidelines and treatment-strategy reports.1,2 In some patients, particularly 
those at risk of exacerbation or with severe symptoms, dual bronchodilation can also 
be considered as initial therapy.1
Long-acting bronchodilator monotherapy has benefits across a range of param-
eters (airflow limitation,3–8 dyspnea,3,4,8 physical activity/exercise capacity,9–12 health 
status,3,4,6–8 and preventing exacerbations);4,8,13,14 however, many patients remain 
symptomatic despite treatment.15 When symptoms are uncontrolled or exacerbations 
occur, treatment should be adjusted with the aim of providing better symptom relief 
and reducing exacerbation risk. Identifying the need for treatment modification can 
be challenging, as patients with COPD often reduce physical activity levels in order 
to reduce symptom intensity, which complicates eliciting symptom burden.16
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Dual bronchodilation improves lung function compared 
with a single bronchodilator; however, when comparing 
active treatments for other outcomes (eg, Transition 
Dyspnea Index, St George’s Respiratory Questionnaire) in 
clinical trials, the magnitude of effect is often not marked. 
For such outcomes, responder analyses (the proportion of 
patients achieving a specified treatment benefit) can indi-
cate the likelihood of clinically important changes for an 
individual.17–26 Currently, there are no clear recommendations 
on which clinical indicators would prompt a patient and phy-
sician to consider stepping up treatment from mono- to dual 
bronchodilation or whether some patients should be started 
on dual therapy earlier in an attempt to maintain exercise 
capacity. The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) has issued some general criteria of escalat-
ing or de-escalating treatment, based on persistent symptoms 
and further exacerbations.1 In this paper, we discuss what 
might trigger physicians to consider stepping up from mono- 
to dual therapy with long-acting bronchodilators and what 
further data are required to help physicians decide if step-up 
therapy is appropriate for their patient.
Relevant medical literature on long-acting bronchodi-
lator monotherapy, dual bronchodilation, and/or inhaled 
corticosteroids (ICSs) plus long-acting β
2
-agonists (LABAs) 
was identified by searching the PubMed (Medline) database 
for articles published in English since 2005. Search terms were 
“chronic obstructive pulmonary disease” OR “COPD” AND 
“long-acting β
2
-agonist”, “long-acting muscarinic antagonist” 
OR “anti-cholinergic”, “LABA/LAMA” OR “dual broncho-
dilation”, “tiotropium”, “salmeterol”, “salmeterol/fluticasone 
propionate”, “IND/GLY”, “indacaterol”, “glycopyrronium”, 
“olodaterol”, “umeclidinium”, “vilanterol”, “UMEC/VI”, 
“formoterol”, “aclidinium”, and “arformoterol”. Results were 
filtered manually to identify studies of long-acting bronchodi-
lation monotherapy reporting effects on lung function and/or 
patient reported outcomes in comparison with placebo and 
dual bronchodilation or ICS/LABA combinations in patients 
with COPD (Table 1). The authors have additionally selected 
papers that are relevant to clinical practice at the time of pub-
lication, and provide their opinions on the evolving therapy 
area of COPD management.
What is the rationale for 
switching from mono- to dual 
bronchodilation?
LABAs and long-acting muscarinic antagonists (LAMAs) 
act via different mechanisms; when used together in patients 
with COPD, they exert additional bronchodilating effects.27,28 
Muscarinic receptors are expressed in the human lung, 
and are also localized in the smooth muscle of all airways, 
with a higher density of receptors in the larger airways. 
β
2
-adrenoceptors are abundantly expressed on human airway 
smooth muscle. The density of the receptors is the same 
throughout the different airway levels, which is particularly 
important in COPD, as the small airways are affected. Bron-
chodilation can thus be achieved through stimulation of the 
β
2
-adrenoceptors with BAs or by inhibiting the action of 
acetylcholine at muscarinic receptors with MAs, indirectly 
leading to smooth-muscle relaxation.29 Multiple studies have 
assessed whether LABA/LAMA dual bronchodilation results 
in additional improvements in lung function, exacerbation 
rates, achievement of minimal clinically important differ-
ences in Transition Dyspnea Index and St George’s Respi-
ratory Questionnaire scores (Table 1), and other outcome 
measures when compared with monobronchodilation. In 
patients with moderate COPD who remained symptomatic 
despite LAMA monotherapy, the step-up to dual broncho-
dilation significantly improved lung function compared 
with continuation of previous treatment.30 Another study by 
Donohue et al measured the efficacy of dual bronchodilation 
(umeclidinium/vilanterol 62.5/25 μg; GlaxoSmithKline, 
Brentford, Middlesex, UK) in patients identified as respon-
sive or unresponsive to monobronchodilation (umeclidinium 
62.5 μg, vilanterol 25 μg).31 Umeclidinium/vilanterol sig-
nificantly increased lung function versus umeclidinium in 
umeclidinium responders and versus vilanterol in vilanterol 
responders. Notably in umeclidinium and vilanterol nonre-
sponders, lung function was still significantly increased, but 
by a smaller amount.31 The study did not assess the impact 
of mono- versus dual bronchodilation on exacerbations.32,33 
The CRYSTAL study examined directly switching from 
various treatments to glycopyrronium (GLY; Novartis, Basel, 
Switzerland) (50 μg) or indacaterol (IND)/GLY (110/50 μg; 
Novartis) in terms of lung function and symptoms in 
symptomatic patients with moderate COPD. IND/GLY sig-
nificantly improved lung function and dyspnea after direct 
switch from LAMA, LABA, or ICS/LABA.34
Activity limitation is an important feature of COPD, with 
dyspnea, deteriorating physical conditioning, and avoidance 
of activity contributing to a vicious circle of decline.16 Physi-
cal inactivity is associated with adverse clinical outcomes, 
including hospitalizations and mortality. Increasing activity 
is thus crucial for effective management strategies that could 
improve long-term outcomes in COPD.35 Improving physi-
cal activity and exercise capacity are closely related clinical 
outcomes in COPD; however, it is important to make a 
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ce
s 
fo
r 
Fe
v
1 a
nd
 F
v
C
 
be
tw
ee
n 
th
e 
im
pr
ov
em
en
ts
 w
ith
 
T
IO
 +
 IN
D
 a
nd
 t
ho
se
 w
ith
 T
IO
 
al
on
e 
an
d 
th
os
e 
w
ith
 IN
D
 a
lo
ne
 
w
er
e 
si
gn
ifi
ca
nt
 (
P,
0.
05
)
N
R
N
R
Im
ra
n 
 
et
 a
l97
R
an
do
m
iz
ed
, d
ou
bl
e-
bl
in
d,
 P
BO
-
co
nt
ro
lle
d,
 a
ct
iv
e 
dr
ug
-c
on
tr
ol
le
d 
pa
ra
lle
l-d
es
ig
n 
st
ud
y;
 4
2 
m
od
er
at
e 
C
O
PD
 p
at
ie
nt
s 
w
ith
ou
t 
an
y 
ot
he
r 
co
m
or
bi
di
ty
T
IO
 (
m
or
ni
ng
) 
an
d 
FO
R
b -
m
at
ch
ed
 P
BO
 (
ev
en
in
g)
, T
IO
/
FO
R
 (
m
or
ni
ng
) 
an
d 
FO
R
-
m
at
ch
ed
 P
BO
 (
ev
en
in
g)
, a
nd
 
T
IO
/F
O
R
 (
m
or
ni
ng
) 
an
d 
FO
R
 
(e
ve
ni
ng
)
N
o 
lu
ng
-fu
nc
tio
n 
ad
va
nt
ag
e 
of
 
ad
di
ng
 F
O
R
 O
D
 o
r 
BI
D
 t
o 
T
IO
N
R
N
R
Ja
ya
ra
m
  
et
 a
l98
D
ou
bl
e-
bl
in
d,
 r
an
do
m
iz
ed
, c
ro
ss
ov
er
 
st
ud
y;
 3
8 
pa
tie
nt
s 
w
ith
 m
od
er
at
e–
se
ve
re
 C
O
PD
Pa
tie
nt
s 
on
 T
IO
 w
er
e 
ra
nd
om
iz
ed
 t
o 
re
ce
iv
e 
ei
th
er
 
FO
R
a  o
r 
PB
O
 fo
r 
6 
w
ee
ks
; 
fo
llo
w
in
g 
a 
2-
w
ee
k 
w
as
ho
ut
 
pe
ri
od
, p
ar
tic
ip
an
ts
 c
ro
ss
ed
 
ov
er
 t
o 
th
e 
al
te
rn
at
e 
ar
m
 o
f 
th
er
ap
y 
fo
r 
a 
fu
rt
he
r 
6 
w
ee
ks
Fe
v
1 i
nc
re
as
ed
 in
 b
ot
h 
gr
ou
ps
 
(1
60
 m
L 
co
m
bi
na
tio
n 
th
er
ap
y 
vs
 3
0 
m
L 
T
IO
), 
w
ith
 a
 m
ea
n 
di
ffe
re
nc
e 
of
 1
10
 m
L 
(9
5%
 
C
I -
10
0–
32
0;
 P
=0
.0
7)
 b
et
w
ee
n 
gr
ou
ps
N
R
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
s 
be
tw
ee
n 
gr
ou
ps
 w
er
e 
sh
ow
n 
fo
r 
lu
ng
 fu
nc
tio
n,
 s
ym
pt
om
 
sc
or
es
, o
r 
qu
al
ity
 o
f l
ife
M
ah
le
r 
et
 a
l43
T
w
o 
id
en
tic
al
ly
 d
es
ig
ne
d,
 r
an
do
m
iz
ed
, 
do
ub
le
-b
lin
d,
 1
2-
w
ee
k 
st
ud
ie
s;
 
2,
27
6 
pa
tie
nt
s 
w
ith
 m
od
er
at
e–
se
ve
re
 C
O
PD
IN
D
 1
50
 m
g 
O
D
 o
r 
m
at
ch
in
g 
PB
O
; a
ll 
pa
tie
nt
s 
co
nc
ur
re
nt
ly
 
re
ce
iv
ed
 o
pe
n-
la
be
l T
IO
  
18
 m
g 
O
D
Su
pe
ri
or
ity
 o
f I
N
D
 +
 T
IO
 v
s 
 
T
IO
 +
 P
BO
 d
em
on
st
ra
te
d 
fo
r 
Fe
v
1 A
U
C
5–
48
0 m
in
 a
t 
w
ee
k 
12
, 
w
ith
 d
iff
er
en
ce
s 
of
 1
30
 m
L 
(9
5%
 
C
I 1
00
–1
50
) 
an
d 
12
0 
m
L 
(9
5%
 
C
I 9
0–
14
0)
 in
 s
tu
di
es
 1
 a
nd
 2
, 
re
sp
ec
tiv
el
y 
(b
ot
h 
P,
0.
00
1)
N
R
N
R
M
al
ek
i-
Y
az
di
  
et
 a
l22
24
-w
ee
k,
 P
ha
se
 II
I, 
m
ul
tic
en
te
r,
 
ra
nd
om
iz
ed
, b
lin
de
d,
 d
ou
bl
e-
du
m
m
y,
 
pa
ra
lle
l-g
ro
up
 s
tu
dy
; 1
,1
91
 m
od
er
at
e–
ve
ry
 s
ev
er
e 
C
O
PD
 p
at
ie
nt
s
U
M
eC
/v
I 6
2.
5/
25
 μ
g 
O
D
 o
r 
T
IO
 1
8 
μg
 O
D
A
n 
im
pr
ov
em
en
t 
of
 0
.1
12
 L
 (
95
%
 
C
I 0
.0
81
–0
.1
44
) 
in
 t
ro
ug
h 
Fe
v
1 a
t 
da
y 
16
9 
w
as
 o
bs
er
ve
d 
fo
r 
U
M
eC
/
v
I 6
2.
5/
25
 μ
g 
vs
 T
IO
 1
8 
μg
O
n-
tr
ea
tm
en
t 
ex
ac
er
ba
tio
ns
 o
cc
ur
re
d 
in
 
4%
 o
f p
at
ie
nt
s 
tr
ea
te
d 
w
ith
 U
M
eC
/v
I a
nd
 
6%
 o
f t
ho
se
 t
re
at
ed
 w
ith
 T
IO
 (
ha
za
rd
 r
at
io
 
[9
5%
 C
I] 
0.
5 
[0
.3
–1
], 
P=
0.
04
4)
N
R
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Sa
lv
i e
t 
al
99
R
an
do
m
iz
ed
, d
ou
bl
e-
bl
in
d,
 
m
ul
tic
en
te
r,
 c
ro
ss
ov
er
 s
tu
dy
;  
44
 C
O
PD
 p
at
ie
nt
s
Si
ng
le
 d
os
e 
of
 1
8 
μg
 o
f T
IO
 v
s 
a 
si
ng
le
 d
os
e 
of
 a
 c
om
bi
na
tio
n 
of
 T
IO
/F
O
R
 1
8/
12
 μ
g
C
om
bi
na
tio
n 
of
 T
IO
/F
O
R
 s
ho
w
ed
 
fa
st
er
 o
ns
et
 o
f b
ro
nc
ho
di
la
to
r 
re
sp
on
se
 (
P,
0.
01
 fo
r 
Fe
v
1 a
nd
 
Fv
C
), 
a 
gr
ea
te
r 
m
ea
n 
m
ax
im
um
 
ch
an
ge
 in
 F
ev
1 (
P=
0.
01
) 
an
d 
Fv
C
 (
P=
0.
00
8)
, a
nd
 g
re
at
er
 
A
U
C
0–
24
 h 
va
lu
es
 fo
r 
Fe
v
1
N
R
N
R
Si
ng
h 
 
et
 a
l23
24
-w
ee
k,
 d
ou
bl
e-
bl
in
d,
 r
an
do
m
iz
ed
, 
pa
ra
lle
l-g
ro
up
, a
ct
iv
e-
 a
nd
 P
BO
-
co
nt
ro
lle
d,
 m
ul
tic
en
te
r 
st
ud
y;
  
1,
72
9 
pa
tie
nt
s 
w
ith
 C
O
PD
A
C
L/
FO
R
 4
00
/1
2 
μg
 B
ID
, 
40
0/
6 
μg
 B
ID
, A
C
L 
40
0 
μg
 
BI
D
, F
O
R
c  1
2 
μg
 B
ID
 o
r 
PB
O
 B
ID
A
t 
w
ee
k 
24
, A
C
L/
FO
R
 le
d 
to
 
si
gn
ifi
ca
nt
 im
pr
ov
em
en
ts
 fr
om
 
ba
se
lin
e 
in
 1
-h
ou
r 
po
st
do
se
 F
ev
1 
vs
 A
C
L 
(P
,
0.
00
1 
fo
r 
bo
th
 d
os
es
) 
an
d 
tr
ou
gh
 F
ev
1 v
s 
FO
R
 (
P,
0.
01
 
fo
r 
bo
th
 d
os
es
); 
co
pr
im
ar
y 
en
d 
po
in
ts
A
C
L/
FO
R
 4
00
/1
2 
μg
 a
nd
 4
00
/6
 μ
g 
re
du
ce
d 
th
e 
H
C
R
U
 r
at
e 
of
 e
xa
ce
rb
at
io
ns
 o
f a
ny
 
se
ve
ri
ty
 b
y 
11
%
 a
nd
 2
%
, r
es
pe
ct
iv
el
y,
 
co
m
pa
re
d 
w
ith
 A
C
L 
(n
ot
 s
ig
ni
fic
an
t)
, a
nd
 b
y 
36
%
 a
nd
 3
0%
, r
es
pe
ct
iv
el
y,
 c
om
pa
re
d 
w
ith
 
FO
R
 (
bo
rd
er
lin
e 
si
gn
ifi
ca
nc
e 
fo
r 
40
0/
12
 μ
g,
 
no
t 
si
gn
ifi
ca
nt
 fo
r 
40
0/
6 
μg
)
A
C
L/
FO
R
 4
00
/1
2 
μg
 a
nd
 4
00
/6
 μ
g 
re
du
ce
d 
th
e 
eX
A
C
T
 r
at
e 
of
 e
xa
ce
rb
at
io
ns
 o
f a
ny
 
se
ve
ri
ty
 b
y 
22
%
 a
nd
 9
%
, r
es
pe
ct
iv
el
y,
 
co
m
pa
re
d 
w
ith
 A
C
L 
(b
or
de
rl
in
e 
si
gn
ifi
ca
nc
e 
fo
r 
40
0/
12
 μ
g,
 n
ot
 s
ig
ni
fic
an
t 
fo
r 
40
0/
6 
μg
); 
th
is
 r
at
e 
ch
an
ge
d 
by
 -
14
%
 a
nd
 +
1%
, 
re
sp
ec
tiv
el
y,
 c
om
pa
re
d 
w
ith
 F
O
R
 (
no
t 
si
gn
ifi
ca
nt
)
T
he
re
 w
as
 a
 n
on
si
gn
ifi
ca
nt
 
tr
en
d 
to
w
ar
d 
an
 in
cr
ea
se
 in
 
th
e 
pr
op
or
tio
n 
of
 p
at
ie
nt
s 
ac
hi
ev
in
g 
th
e 
M
C
ID
 in
 T
D
I 
w
ith
 A
C
L/
FO
R
 4
00
/1
2 
μg
 
an
d 
40
0/
6 
μg
 v
er
su
s 
th
e 
m
on
oc
om
po
ne
nt
s
C
or
re
sp
on
di
ng
 p
ro
po
rt
io
ns
 fo
r 
SG
R
Q
 w
er
e 
N
R
, b
ut
 a
ll 
ac
tiv
e 
tr
ea
tm
en
ts
 w
er
e 
as
so
ci
at
ed
 
w
ith
 im
pr
ov
em
en
ts
 in
 m
ea
n 
SG
R
Q
 t
ot
al
 s
co
re
 .
4 
un
its
 
(M
C
ID
 $
4 
un
its
)
T
as
hk
in
  
et
 a
l10
0
6-
w
ee
k,
 r
an
do
m
iz
ed
, d
ou
bl
e-
bl
in
d,
 
PB
O
-c
on
tr
ol
le
d,
 p
ar
al
le
l-g
ro
up
 s
tu
dy
; 
13
0 
cu
rr
en
t 
or
 fo
rm
er
 s
m
ok
er
s 
w
ith
 
C
O
PD
FO
R
b  2
0 
μg
 B
ID
 +
 T
IO
 1
8 
μg
 
O
D
 o
r 
PB
O
 +
 T
IO
 1
8 
μg
 O
D
Fe
v
1 A
U
C
0–
3 h
 a
t 
w
ee
k 
6 
w
as
 
si
gn
ifi
ca
nt
ly
 g
re
at
er
 w
ith
 F
O
R
 
+ 
T
IO
 v
s 
PB
O
 +
 T
IO
 (
1.
52
 L
 v
s 
1.
34
 L
, P
,
0.
00
01
)
Fe
w
er
 p
at
ie
nt
s 
tr
ea
te
d 
w
ith
 F
O
R
 +
 T
IO
 
ex
pe
ri
en
ce
d 
ex
ac
er
ba
tio
ns
 v
s 
th
os
e 
tr
ea
te
d 
w
ith
 P
BO
 +
 T
IO
 (
4.
5%
 v
s 
7.
9%
, s
ta
tis
tic
al
 
co
m
pa
ri
so
ns
 N
R
)
N
R
T
as
hk
in
  
et
 a
l10
1
12
-w
ee
k,
 a
ct
iv
e-
co
nt
ro
lle
d,
 
ra
nd
om
iz
ed
, d
ou
bl
e-
bl
in
d,
 m
ul
tic
en
te
r 
tr
ia
l; 
25
5 
pa
tie
nt
s 
w
ith
 C
O
PD
FO
R
d  1
2 
μg
 B
ID
 +
 T
IO
 1
8 
μg
 
O
D
 o
r 
T
IO
 1
8 
μg
 O
D
G
re
at
er
 im
pr
ov
em
en
ts
 in
 F
ev
1 
A
U
C
0–
4 h
 w
er
e 
se
en
 w
ith
 F
O
R
 
+ 
T
IO
 v
s 
T
IO
 a
t 
al
l t
im
e 
po
in
ts
 
(P
,
0.
01
)
ex
ac
er
ba
tio
ns
 o
cc
ur
re
d 
in
 1
7%
 o
f p
at
ie
nt
s 
in
 t
he
 F
O
R
 +
 T
IO
 g
ro
up
 a
nd
 1
1%
 o
f t
he
 
T
IO
 g
ro
up
 (
P=
0.
14
9)
T
as
hk
in
  
et
 a
l10
2
2-
w
ee
k,
 r
an
do
m
iz
ed
, m
od
ifi
ed
-b
lin
d,
 
pa
ra
lle
l-g
ro
up
 s
tu
dy
; 2
35
 p
at
ie
nt
s 
w
ith
 
C
O
PD
A
R
F 
15
 μ
g 
BI
D
, T
IO
 1
8 
μg
 
BI
D
, o
r 
co
m
bi
ne
d 
th
er
ap
y 
(s
eq
ue
nt
ia
l d
os
in
g 
of
 A
R
F 
 
15
 μ
g 
BI
D
 a
nd
 T
IO
 1
8 
μg
 O
D
)
M
ea
n 
Fe
v
1 A
U
C
0–
24
 h 
im
pr
ov
ed
 
si
m
ila
rl
y 
fr
om
 b
as
el
in
e 
fo
r 
A
R
F 
(0
.1
 L
) 
an
d 
T
IO
 (
0.
08
 L
) 
tr
ea
tm
en
t 
gr
ou
ps
 a
nd
 g
re
at
er
 
fo
r 
th
e 
co
m
bi
ne
d 
th
er
ap
y 
gr
ou
p 
(0
.2
2 
L,
 a
ll 
P,
0.
00
5)
ex
ac
er
ba
tio
ns
 o
cc
ur
re
d 
in
 3
.9
%
 o
f p
at
ie
nt
s 
in
 t
he
 A
R
F 
gr
ou
p;
 n
o 
ex
ac
er
ba
tio
ns
 w
er
e 
re
po
rt
ed
 in
 t
he
 T
IO
 o
r 
A
R
F 
+ 
T
IO
 g
ro
up
s 
(s
ta
tis
tic
al
 c
om
pa
ri
so
ns
 N
R
)
A
 g
re
at
er
 p
ro
po
rt
io
n 
of
 
pa
tie
nt
s 
in
 t
he
 c
om
bi
ne
d-
th
er
ap
y 
gr
ou
p 
ha
d 
$
1-
un
it 
im
pr
ov
em
en
t 
in
 T
D
I (
77
.9
%
) 
vs
 A
R
F 
(6
6.
7%
) 
or
 T
IO
 (
57
.1
%
) 
m
on
ot
he
ra
pi
es
; t
hi
s 
di
ffe
re
nc
e 
w
as
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t 
fo
r 
co
m
bi
ne
d 
th
er
ap
y 
vs
 T
IO
 (
95
%
 
C
I 0
.0
6–
0.
35
)
SG
R
Q
 N
R
(C
on
tin
ue
d)
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T
ab
le
 1
 (
Co
nt
in
ue
d)
St
ud
y
D
es
ig
n 
an
d 
pa
ti
en
ts
T
re
at
m
en
t
Lu
ng
-f
un
ct
io
n 
re
sp
on
se
P
re
ve
nt
io
n 
of
 C
O
P
D
 e
xa
ce
rb
at
io
ns
M
C
ID
 in
 T
D
I a
nd
 S
G
R
Q
T
er
za
no
  
et
 a
l10
3
R
an
do
m
iz
ed
, b
lin
d,
 c
ro
ss
ov
er
 s
tu
dy
; 
80
 p
at
ie
nt
s 
w
ith
 C
O
PD
Fi
ve
 d
iff
er
en
t b
ro
nc
ho
di
la
to
r 
30
-d
ay
 tr
ea
tm
en
ts
 in
 r
an
do
m
 
or
de
r;
 tr
ea
tm
en
ts
 w
er
e:
 T
IO
 
18
 μ
g 
O
D
 (8
 a
m
), 
TI
O
 1
8 
μg
 
(8
 a
m
) +
 F
O
Ra
 1
2 
μg
 (8
 p
m
), 
FO
R 
12
 μ
g 
BI
D
 (8
 a
m
 a
nd
 
8 
pm
), 
TI
O
 1
8 
μg
 (8
 a
m
) +
 
FO
R 
12
 μ
g 
BI
D
 (8
 a
m
 a
nd
 8
 
pm
), 
FO
R 
12
 μ
g 
BI
D
 (8
 a
m
 a
nd
 
8 
pm
) +
 T
IO
 1
8 
μg
 O
D
 (8
 p
m
)
T
IO
 1
8 
μg
 (
8 
am
) 
+ 
FO
R
  
12
 μ
g 
BI
D
 (
8 
am
 a
nd
 8
 p
m
) 
w
as
 a
ss
oc
ia
te
d 
w
ith
 la
rg
er
 
da
ily
 c
ha
ng
es
 in
 F
ev
1 a
t 
da
y 
30
 
co
m
pa
re
d 
w
ith
 t
he
 m
on
ot
he
ra
py
 
tr
ea
tm
en
ts
N
R
N
R
va
n 
N
oo
rd
 
et
 a
l10
4
R
an
do
m
iz
ed
, o
pe
n-
la
be
l, 
PB
O
-
co
nt
ro
lle
d,
 t
hr
ee
-w
ay
 c
ro
ss
ov
er
 s
tu
dy
; 
95
 p
at
ie
nt
s 
w
ith
 C
O
PD
T
IO
 1
8 
μg
 O
D
, T
IO
 1
8 
μg
 
O
D
 +
 F
O
R
 1
2 
μg
 O
D
, T
IO
  
18
 μ
g 
O
D
 +
 F
O
R
a  1
2 
μg
 B
ID
A
ve
ra
ge
 F
ev
1 A
U
C
0–
24
 h 
im
pr
ov
ed
 
by
 0
.0
8 
L 
w
ith
 T
IO
, b
y 
0.
16
 L
 
w
ith
 T
IO
 +
 F
O
R
 O
D
, a
nd
 b
y 
0.
2 
L 
w
ith
 T
IO
 +
 F
O
R
 B
ID
 
(a
ll 
P,
0.
01
)
N
R
N
R
va
n 
N
oo
rd
 
et
 a
l10
5
R
an
do
m
iz
ed
, d
ou
bl
e-
bl
in
d,
 t
hr
ee
-w
ay
, 
cr
os
so
ve
r 
st
ud
y;
 7
1 
pa
tie
nt
s 
w
ith
 
C
O
PD
T
IO
 1
8 
μg
 O
D
, F
O
R
 1
2 
μg
 
BI
D
, o
r 
bo
th
 c
om
bi
ne
d 
O
D
 
fo
r 
th
re
e 
6-
w
ee
k 
pe
ri
od
s
C
om
bi
na
tio
n 
th
er
ap
y 
pr
ov
id
ed
 
gr
ea
te
r 
im
pr
ov
em
en
t 
in
 F
ev
1 t
ha
n 
m
on
ot
he
ra
pi
es
 (
P,
0.
05
)
ex
ac
er
ba
tio
ns
 o
cc
ur
re
d 
in
 1
4.
1%
 o
f p
at
ie
nt
s 
in
 t
he
 F
O
R
 +
 T
IO
 g
ro
up
, 2
0.
3%
 in
 t
he
 F
O
R
 
gr
ou
p 
an
d 
5.
7%
 in
 t
he
 T
IO
 g
ro
up
 (
st
at
is
tic
al
 
co
m
pa
ri
so
ns
 N
R
)
N
R
va
n 
N
oo
rd
 
et
 a
10
6
6-
w
ee
k,
 r
an
do
m
iz
ed
, d
ou
bl
e-
bl
in
d,
 
fo
ur
-w
ay
 c
ro
ss
ov
er
 s
tu
dy
 o
f 6
-w
ee
k 
tr
ea
tm
en
t 
pe
ri
od
s;
 9
5 
pa
tie
nt
s 
w
ith
 
C
O
PD
T
IO
 1
8 
μg
 O
D
 +
 S
A
L 
50
 μ
g 
(O
D
 o
r 
BI
D
) 
vs
 r
es
pe
ct
iv
e 
m
on
ot
he
ra
pi
es
T
IO
 +
 S
A
L 
pr
ov
id
ed
 g
re
at
er
 
im
pr
ov
em
en
ts
 v
s 
re
sp
ec
tiv
e 
m
on
ot
he
ra
pi
es
 in
 F
ev
1 A
U
C
0–
24
 h 
(P
,
0.
00
01
)
ex
ac
er
ba
tio
ns
 o
cc
ur
re
d 
in
 5
.4
%
 o
f p
at
ie
nt
s 
in
 t
he
 T
IO
 +
 S
A
L 
O
D
 g
ro
up
, 7
.6
%
 o
f t
he
 
T
IO
 +
 S
A
L 
BI
D
 g
ro
up
, 1
6.
1%
 o
f t
he
 S
A
L 
BI
D
 g
ro
up
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distinction between the two. Physical activity reflects what 
someone actually does that results in energy expenditure, 
whereas exercise capacity indicates what a person is physi-
cally capable of doing.36 Clinical trials are yet to find a clear 
association between physical activity and exercise capacity. 
This may be because physical activity is hard to assess, as it 
is measured by direct observation, such as questionnaires or 
patient diaries, which can be subjective and a time-consuming 
method to assess in large populations.35 This may explain why 
studies focus more on exercise capacity in clinical trials and 
a clear association is yet to be found.
Monobronchodilators have been shown to improve 
exercise tolerance in COPD patients,9,12 and while some 
early exercise studies of dual bronchodilators demonstrated 
benefit versus placebo, benefit versus monobronchodilators 
was not seen,37,38 perhaps due to the absence of a training or 
rehabilitation component within the older study designs. 
The more recent PHYSACTO study was designed to 
evaluate the effects of bronchodilation alone or in combina-
tion with 8 weeks of additional exercise training on exercise 
capacity, and level of physical activity in patients with 
moderate–severe COPD. All patients were enrolled in a 
12-week self-management behavior-modification program, 
focused on improving patient engagement in, and maintenance 
of, physical activity.39 PHYSACTO found that tiotropium 
(TIO)/olodaterol (Boehringer Ingelheim International GmbH, 
Ingelheim am Rhein, Germany), either alone or in combination 
with exercise training, did not significantly improve physical 
activity compared with placebo, although a significant reduc-
tion in symptom burden was observed. It is interesting to note 
that self-managed behavior modification alone significantly 
improved physical activity compared with baseline; this may 
have made any detectable differences in treatment benefit dif-
ficult. Furthermore, there was no correlation between exercise 
tolerance and change in physical activity.36
Recently, the dual bronchodilator IND/GLY was 
shown to reduce hyperinflation and improve daily physical 
activity levels compared with placebo, despite no patient 
education or lifestyle advice, suggesting a potential role 
in major clinical concerns in COPD.40 Therefore, a picture 
of the potential benefit of dual bronchodilation on activity 
is emerging; however, as lung-function decline in COPD 
is progressive, it is unknown whether earlier intervention 
with these treatments may be more beneficial in preserving 
physical ability. The impact of delaying step-up therapies 
on clinical parameters, such as activity levels, has yet to 
be established.
In symptomatic patients, the recently updated GOLD 
strategy document recommends that patients at lower risk of 
exacerbations (GOLD group B) should be treated with a long-
acting bronchodilator, escalating to dual bronchodilation if 
symptoms persist.1 The LABA/LAMA IND/GLY has been 
shown to reduce dyspnea significantly compared with placebo 
and TIO monotherapy in dyspneic patients (modified Medical 
Research Council (mMRC) dyspnea scale score .2).41 This 
finding is supported by another post hoc analysis indicating 
that IND/GLY significantly reduced dyspnea compared with 
TIO in patients with a baseline dyspnea index score #7.42 
Similarly, for the nonexacerbator phenotype, GesEPOC 
(Guía Española de la Enfermedad Pulmonar Obstructiva 
Crónica) recommends initial therapy with LAMA or LABA 
monotherapy escalating to second-line therapy with a LABA/
LAMA combination.2 GesEPOC cites evidence from rep-
licate studies demonstrating IND plus TIO to be superior 
to TIO alone,43 and another demonstrating IND/GLY to be 
superior to the ICS/LABA combination salmeterol/flutica-
sone (SFC; GlaxoSmithKline) on lung-function parameters in 
nonexacerbating patients to support the recommendation.2,44 
In high-risk symptomatic patients (GOLD D), GOLD recom-
mends LABA/LAMA as the preferred choice.1 If a single 
bronchodilator is chosen as initial treatment, LAMA is 
recommended, escalating to LABA/LAMA if exacerbations 
persist.1 SPARK and FLAME demonstrated that IND/GLY 
significantly reduced COPD exacerbations versus the LAMA 
GLY and SFC in patients with severe–very severe COPD.45,46 
Additionally, both studies found a significant reduction in 
rescue-medication use versus the active comparators.45,46 
Notably, the safety profile of dual bronchodilators is similar to 
that observed with placebo and individual monocomponents, 
with a comparable incidence of adverse events and serious 
adverse events.17,19,23 Furthermore, dual bronchodilators are 
associated with a lower incidence of pneumonia and oral 
candidiasis than ICS/LABA (SFC).46–49
Role of ICS
According to GOLD and GesEPOC, initial therapy with 
ICS/LABA may be first choice in those with suggestions of 
a steroid-responsive component to their airway disease, eg, 
those with a confirmed comorbid diagnosis of asthma, or those 
with a biomarker signature of T
H
2 disease.1,2,50 If exacerbations 
persist despite therapy with LABA/LAMA or ICS/LABA, 
treatment can be escalated to triple therapy (ICS/LABA/
LAMA).1,2 Trial evidence showing a reduction in exacerba-
tions with ICS/LABA compared with one or both components 
alone forms the basis for such recommendations; in the 
majority of these trials, patients had a history of one or more 
exacerbations in the year prior to the study.5,51–54 The addition 
of an ICS to a LABA/LAMA has not been studied specifically 
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to date in any completed trials. Findings from the ongoing 
IMPACT and TRIBUTE are eagerly anticipated; both studies 
will investigate the efficacy of triple therapy vs LABA/LAMA 
in GOLD D patients.55,56 Post hoc analyses have suggested 
greater efficacy of ICS vs LABA monotherapy in patients 
with a blood eosinophil count $2% or $297.8 cells/μL.57,58 
However, recently published data from FLAME demonstrated 
that a blood eosinophil count $2% was not a useful clinical 
biomarker in identifying patients who are likely to have a 
response to an ICS/LABA regimen when compared with a 
LABA/LAMA.46,59 Following ICS withdrawal, one analysis 
found an increased exacerbation rate in patients with higher 
eosinophil counts,60 and when stratified by exacerbation his-
tory, high eosinophils ($400 cells/μL) were only associated 
with increased exacerbations in patients with two or more 
exacerbations in the previous year.61 Most studies showing 
an effect of an ICS have included participants with an FEV
1
 
,50% predicted.62 
Among patients at low risk of future exacerbation, a 
considerable proportion of patients inappropriately receive 
ICS/LABA, either alone or as part of triple therapy.63,64 
Management of exacerbating patients has largely focused 
on maximizing bronchodilation, rather than prescribing 
an ICS-containing regimen.1,65 Due to the increased risk of 
pneumonia with an ICS,66 GOLD 2017 recommends that 
ICS withdrawal be considered if no benefit is seen.1 This 
recommendation is based on findings from WISDOM, 
which demonstrated that ICSs can be withdrawn in COPD 
patients without increased risk of exacerbation, provided 
adequate bronchodilator therapy is in place.67 If patients 
develop further exacerbations despite treatment with ICS/
LABA/LAMA, the addition of a macrolide, roflumilast, car-
bocysteine, or theophylline should be considered, depending 
on patient phenotype.1,2,68
Which criteria might be most useful 
to guide treatment step-up from 
mono- to dual bronchodilation?
While different guidelines and strategy documents provide 
advice on the parameters to monitor routinely, namely lung-
function measurements, symptoms, exacerbations, imaging, 
and smoking status,1,2 guidance related to the criteria that 
warrant step-up from mono- to dual bronchodilation are 
generally unclear, due to a lack of specific evidence.
The GesEPOC guidelines2 state that dual bronchodilation 
“should be tried” in symptomatic patients or those with evi-
dent exercise limitations following bronchodilator monother-
apy. The National Institute for Health and Care Excellence 
guidelines provided more detailed recommendations 
compared with other guidance at the time of their publication; 
however, it is generally recognized that these have not been 
updated since 2010, and more evidence has become available 
since their publication.69 Recently, the GOLD recommenda-
tions have provided more specific guidance for stepping up 
from mono- to dual bronchodilation, ie, in group B patients 
with “persistent symptoms” and in group C patients with 
“persistent exacerbations”.1
Although a lack of evidence makes any particular recom-
mendations speculative, several factors offer potential in aid-
ing decisions on whether patients should change treatments, as 
shown in Table 2 and described in the following sections.
Inadequate response to initial treatment
In clinical practice, response to COPD pharmacotherapy 
and other medical treatment is often judged on the patient’s 
symptomatic response, eg, reduced breathlessness, increased 
exercise capacity, or reduced need for rescue medication.1 
In the absence of other evidence, this may provide an indica-
tion to the physician as to whether a response is sufficient. 
This is inevitably subjective, as it is rare to abolish symptoms 
completely in COPD patients, and clinicians and patients must 
justify whether the treatment response is sufficiently large to 
make symptoms bearable and whether the change in func-
tional capacity is adequate for the patient’s needs. An objec-
tive measure, such as the COPD Assessment Test (CAT), may 
be useful in assessing patient response to treatment and can 
be used routinely every 2–3 months.70 Research is ongoing 
to understand the minimal clinically relevant change in CAT 
score from one visit to the next, but a development steering 
group suggests a score difference of $2 suggests a clinically 
significant change in health status.70,71 Such a change or lack 
thereof could inform evaluation of treatment response after a 
suitable trial period. Adherence to treatment and inhalation 
technique should be assessed,1 and suboptimal adherence and 
inhalation technique should be addressed before concluding 
that current therapy is insufficient. If the patient or physician 
perceives inadequate symptomatic relief, assuming adher-
ence to therapy and inhalation technique are acceptable, 
a change in treatment regimen should be considered.
Increased use of rescue medication
In our clinical experience, patients with a sustained daily 
requirement for short-acting bronchodilators may benefit from 
treatment intensification with long-acting bronchodilators. A 
retrospective analysis of clinical trial data (810 patients with 
moderate–very severe COPD) showed that short-acting BA 
reliever use is a predictor of short- and long-term (3-week 
and 10-month) exacerbation risk in patients with a history of 
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exacerbations receiving budesonide/formoterol (AstraZeneca, 
Luton, UK) or formoterol.72 Exacerbation rate increased sub-
stantially with increasing reliever-medication use. Compared 
with patients who used a mean of fewer than two inhalations/
day of reliever medication over a 2-month period, those who 
used a mean of 2–5, 6–9, and $10 inhalations/day (over 
the same time period) experienced 21% (P=0.22), 67% 
(P=0.0016), and 135% (P,0.001) higher exacerbation rates, 
respectively, over the following 10 months.72
worsening of symptoms
Worsening of COPD symptoms on clinical evaluation may 
lead patients and physicians to consider stepping up treat-
ment. Symptom or health-status assessment scores (eg, using 
the CAT or the Clinical COPD Questionnaire) may also 
inform patient–physician discussions on this topic, but trends 
and changes are more valuable than single measurements.1 
As both questionnaires are short and easy to administer,71,73,74 
these tools could be used at follow-up visits to provide addi-
tional confirmation of disease progression. The mMRC may 
not have sufficient sensitivity for this purpose.75
Suboptimal symptom control across 
the whole day
Although COPD symptoms can vary throughout the day, 
they are known to be problematic during both the day and 
night.76,77 An observational study of patients with stable 
COPD (n=727) reported a significant relationship between 
nighttime, early morning, and daytime symptoms.78 In each 
period, symptoms were associated with worse patient-
reported outcomes (dyspnea, health status, sleep quality, and 
elevated anxiety and depression levels; all P,0.001 versus 
patients without symptoms in each corresponding period), 
suggesting that improving 24-hour symptom control should 
be an important consideration in the management of COPD. 
Most newer long-acting bronchodilators are effective for the 
full 24 hours after once-daily administration, and may be 
useful in improving overnight symptom control.79
Suboptimal COPD control
The concept of disease control considers the variable nature 
of the disease within the broader context of disease phe-
notype and severity. The two components of the “COPD 
control” concept are impact and stability.80 Impact refers to 
the clinical situation of a patient at a given moment in time, 
and can be measured by such instruments as the CAT, or by 
the degree of dyspnea, the use of rescue medication, the level 
of physical activity, and sputum color.80 Stability refers to 
the temporal evolution of impact over time (ie, by assessing 
impact at more than one time point and determining how 
this has changed or remained the same).80 The concept of 
COPD control has implications for treatment decisions, such 
Table 2 Clinical events or parameters that may indicate a requirement for modifying COPD treatment
Clinical event or parameter Measure
Inadequate response to initial treatment CAT score improvement ,2 following intervention70,71
Insufficient symptomatic relief perceived by patient or physician1
•	 Changes in breathlessness
•	 Changes in ability to carry out activities
•	 Sleep quality
•	 Are improvements worthwhile to patient?
Increased use of rescue medication Sustained, increased requirement for short-acting bronchodilators
•	 eg, $6 inhalations/day of salbutamol72
Hospitalization Any single hospitalization related to COPD or its complications
worsening of symptoms worsening of COPD symptoms on clinical evaluation; deterioration in symptom  
or health-status assessment scores over time
Suboptimal symptom control across the whole day Problematic nighttime, early morning, and/or daytime COPD symptoms
Suboptimal COPD control Patient not achieving individualized treatment objectives in areas relating to COPD 
impact and stability:
•	 CAT/CCQ scores
•	 Degree of dyspnea
•	 Use of rescue medication
•	 Level of physical activity
•	 Sputum color over time
exacerbation events Occurrence of an exacerbation (or hospitalization) after maintenance-treatment initiation
Reduction in lung function (in combination with 
other measures of clinical worsening)
Reduced Fev1 accompanied by an increase in disease severity, symptoms, or exacerbation 
rate, a decrease in exercise tolerance, or COPD comorbidities
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; Fev1, forced expiratory volume in 1 second.
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that treatment may need to be stepped up if control is poor 
or maintained in the same way if there is disease stability. 
The ultimate goal of COPD treatment is optimal COPD 
control, as evidenced by the achievement of individualized 
treatment objectives. The proposal of the concept of control 
in COPD has yet to be validated.
exacerbation events
The occurrence of exacerbations despite initial therapy may 
also be an indicator of the need for treatment escalation, 
such as switching to dual bronchodilation. Whether a single 
exacerbation is sufficient to merit escalation, or whether two 
exacerbations in a 12-month period or a single hospitalization 
should be the trigger, will be a matter of clinical judgment 
and depend to some extent on the severity of the COPD.
Reduction in lung function
Deterioration in lung function alone may not be an appropriate 
reason for switching therapy, as it does not capture the complex-
ity of COPD: at a given level of airflow limitation, there is large 
variability in disease severity, symptoms, exercise tolerance, 
exacerbation rate, and the prevalence of comorbidities.81 How-
ever, a reduction in lung function considered alongside these 
factors may be a trigger for escalating COPD treatment.
Where are the evidence gaps?
Further work is needed to provide clear guidance for physi-
cians regarding which tools and biomarkers can be used 
to assess patients and to guide decisions on which patients 
may need to progress from mono- to dual bronchodilation. 
Similarly, of all patients requiring an increase in medication 
from monotherapy with a long-acting bronchodilator, there 
is a need to clarify between those who would be more likely 
to benefit from a second long-acting bronchodilator and those 
more likely to benefit from an ICS and the effective dose.57,82,83 
Investigations into the potential use of blood eosinophil counts 
as a predictive biomarker of ICS response are ongoing.
There is limited but increasing evidence directly assessing 
the proportion of patients who respond to dual bronchodila-
tion who were uncontrolled with monotherapy. The benefits 
of directly switching from previous COPD treatment to dual 
bronchodilation on lung function and symptoms have been 
demonstrated in both CRYSTAL and a study by Kerwin 
et al.30,34 Donohue et al showed that nonresponders to 
LAMA or LABA monotherapy can experience significant 
and clinically meaningful improvements in lung function 
when treated with a LABA/LAMA combination,31 although 
other clinical outcomes were not evaluated.31 Nonetheless, 
this study supports the findings from many of the studies 
outlined in Table 1 in showing greater improvements in lung 
function with dual bronchodilation versus monotherapy. 
A subgroup analysis of data from SHINE and ILLUMINATE 
(n=2,667), showed that IND/GLY improved lung function 
in patients with moderate–severe COPD who had been 
previously treated with LAMA or LABA monotherapy. 
Improvements in dyspnea and health status with IND/GLY 
were also observed in participants previously receiving 
LAMA.84 However, several of the subgroups analyzed in this 
study were small, notably the prior-LABA-treatment group. 
Furthermore, all patients receiving medications during the 
prescreening of SHINE underwent extensive drug washout, 
except for those receiving short-acting BAs.84
As well as studies examining the magnitude of benefits of 
switching from mono- to dual-bronchodilator therapy, studies 
are required to look at the optimal timing of this escalation. 
It is not known whether greater benefits can be achieved if 
treatment is intensified early in the course of the disease or 
whether delaying the introduction of maximal bronchodilator 
therapy has any impact on overall disease progression.
Various applications of telemedicine and smartphone 
interventions are being investigated in COPD, and reports 
indicate some benefit in terms of reducing exacerbations, 
hospitalizations, and emergency-room visits.85,86 The use 
of smartphones requires effective synergistic strategies to 
improve outcomes,85,87 and a well-designed application could 
facilitate patient monitoring and alert physicians to the need 
to review treatment. With estimates of 2.6 billion smartphone 
owners by the end of 2017,88 the potential benefit of this direct 
interface with the patient should be assessed.
Avoiding unnecessary polypharmacy
In addition to the potential requirement for increasing 
treatment, physicians should be aware of the need to avoid 
unnecessary polypharmacy,1 eg, in patients in whom triple 
therapy, dual-, or monobronchodilation plus ICS therapy has 
been initiated, but who have not responded with perceived 
benefit (eg, symptom improvement) compared with previ-
ous dual therapy or monotherapy, respectively. “Perceived 
benefit” can be challenging to evaluate in clinical practice, 
particularly where the aim of therapy is to reduce exacerba-
tions. For example, it can be difficult to discern whether an 
individual who continues to experience exacerbations follow-
ing the addition of an ICS would have experienced a similar 
number or more of these events without this addition.
There is very little evidence to guide the stepping down 
of treatment between dual and monobronchodilation. 
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There is evidence to support the withdrawal of ICSs in 
some patients receiving triple therapy. In addition to 
WISDOM67 (as mentioned earlier), OPTIMO also assessed 
the withdrawal of ICS therapy in patients at low risk of 
exacerbation receiving maintenance therapy with long-
acting bronchodilators and ICSs. OPTIMO did not find any 
deterioration in lung function or exacerbation rate when 
ICS was withdrawn compared with continued ICS therapy, 
providing regular treatment with long-acting bronchodila-
tors was maintained.89
Despite limited evidence related to stepping down from 
triple or dual therapy, there is general consensus that a large 
number of COPD patients are overtreated, particularly at the 
milder end of the spectrum.64,90,91 Ultimately, the decision to 
continue or withdraw stepped up therapy must be made on a 
patient-to-patient basis and must balance the risk of adverse 
events with any potential impact on lung function, symptoms, 
and exacerbation risk.
Summary
Bronchodilators are central to COPD treatment. Long-acting 
bronchodilators are recommended as initial therapy in 
symptomatic patients, whether or not the patient has a high 
risk of exacerbations. Dual bronchodilation may be suitable 
as a step-up approach in those with persistent symptoms or 
exacerbations. Initial therapy with dual bronchodilation could 
be appropriate for some patients, particularly those at risk of 
exacerbation or with severe symptoms at diagnosis. New evi-
dence shows that LABA/LAMA combinations may reduce 
the rate of exacerbations compared with ICS/LABA, even in 
patients with a history of exacerbations. However, COPD is 
a heterogeneous condition, and an individualized treatment 
approach is required. Currently, it is not clear at which stage 
patients should progress from mono- to dual bronchodilation. 
We have identified and discussed a number of factors that 
may help physicians to identify the point at which patients 
should change treatment, although further work is required 
to clarify specific thresholds (Table 2). This may encompass 
the use of indicators such as symptomatic response, use of 
rescue medication, hospitalizations, disease control, and the 
occurrence of exacerbations. Future research should aim 
to provide a better understanding of when a patient should 
progress treatment, and identify the appropriate tools to 
inform this decision.
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